ライフサイエンスコーパス: apheresis

1 years; 8 patients were on ezetimibe and 7 on apheresis.

2 d-lowering treatment except ezetimibe and/or apheresis.

3 tin 20 mg alone or added to ezetimibe and/or apheresis.

4 r placebo and 15 days later undergo platelet apheresis.

5 a mean of 4 +/- 3 days (range, 2-8 days) of apheresis.

6 CD34+ count of > or = 6/microL and underwent apheresis.

7 in the greatest quantity on the first day of apheresis.

8 iltration plasmapheresis and lipoprotein (a)-apheresis.

9 d predictably mobilizes HPCs and facilitates apheresis.

10 ilial hypercholesterolaemia, with or without apheresis.

11 which is markedly reduced after lipoprotein apheresis.

12 PET imaging 3 days (range 1 to 4 days) after apheresis.

13 th other lipid-lowering therapies, including apheresis.

14 hree (4%) among patients who did not receive apheresis.

15 colony-stimulating factor and collected via apheresis.

16 k of complications from CVC placement before apheresis.

17 eripheral blood stem cells" obtained through apheresis.

18 ry 2 weeks after 12 weeks in patients not on apheresis.

19 ied European guidelines governing the use of apheresis.

20 33% of normal allogeneic sibling donors in 1 apheresis.

21 onal therapy is with statins, ezetimibe, and apheresis.

22 were significantly reduced after lipoprotein apheresis (284 +/- 118 mg/dl vs. 127 +/- 50 mg/dl; p < 0

23 Despite the proven benefits of LDL apheresis, access to this procedure remains limited beca

24 progenitor cells per unit of blood volume of apheresis after A + G administration versus G alone.

25 od (PB) mononuclear cells were collected via apheresis after high-dose cyclophosphamide and granulocy

26 ntinuation, and neonatal and fetal safety of apheresis after one (n=6), two (n=4), or three (n=1) aph

27 ization, intravenous catheter insertion, and apheresis and a median of 9 platelet transfusions was re

28 cyte colony-stimulating factor, underwent an apheresis and electromechanical mapping, and were random

29 Leukoreduction by apheresis and filtration resulted in substantial reducti

30 can be used as a predictor for the timing of apheresis and for estimating PBPC yield.

31 ovascular events, one (3%) among patients on apheresis and three (4%) among patients who did not rece

32 fine the patient population eligible for LDL apheresis and to create unified European guidelines gove

33 bers of mononuclear cells collected per 10-L apheresis and to increased concentrations of progenitors

34 , erythroid burst-forming units (1.8-fold/kg/apheresis), and colony-forming units-granulocyte-macroph

35 dministration of intravenous immunoglobulin, apheresis, and combination therapies using potent immuno

36 yte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas

37 were mobilized by filgrastim, collected via apheresis, and labeled with technetium-99m radioisotope

38 lar regardless of age or use of ezetimibe or apheresis, and was maintained for 12 weeks.

39 Similar changes were observed for the apheresis- and sham-treatment groups for endoscopic remi

40 ing apheresis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration,

41 cytokines, and ongoing trials with leukocyte apheresis are currently under way.

42 telets (SDP) obtained from a single donor by apheresis are indicated to treat acute hemorrhage second

43 Intravenous gamma globulin and selective apheresis are niche therapies appropriate in a few, high

44 were included in this analysis, 34 receiving apheresis at study entry and 14 younger than 18 years.

45 47 of 72 patients not on apheresis at study entry increased evolocumab dosing to

46 s with FH and, moreover, whether lipoprotein apheresis attenuates arterial wall inflammation in FH pa

47 Apheresis began on day 4 of G-CSF administration.

48 SCF and 10 microg/kg/d filgrastim with daily apheresis beginning on day 5 was selected as the optimal

49 d is achieved in most patients with a single apheresis, but an optimal collection usually requires at

50 supports the hypothesis that extracorporeal apheresis can lower circulating sFlt-1 in very preterm p

51 An 8-F 24-cm-long apheresis catheter was placed in the basilic vein with i

52 marrow collection by sequential COBE Spectra apheresis (COBE BCT, Lakewood, CO), CD34+ enrichment usi

53 /=2 x 10(6) CD34(+)/kg recipient weight in 1 apheresis collection to </=10% was not reached.

54 timal proportion of the platelet supply from apheresis collections and the choice of whole-blood-deri

55 At least three daily 12-L apheresis collections were performed on each donor.

56 dration, and reducing blood flow through the apheresis column.

57 fusion increments for platelets derived from apheresis compared with platelet-rich plasma whole-blood

58 ng units-granulocyte-macrophage (2.2-fold/kg/apheresis) compared with regimen G given to the same pat

59 34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.

60 or = 5 x 10(6) CD34+ cells/kg in 4 or fewer apheresis days.

61 ature-based review of the relative merits of apheresis-derived and whole-blood-derived platelets.

62 , and may eventually combine the benefits of apheresis-derived and whole-blood-derived platelets.

63 Apheresis-derived, autologous, lymphocyte-rich cells rad

64 However, criteria for LDL apheresis eligibility and the percentage of patients rec

65 Platelet transfusions total >2.17 million apheresis-equivalent units per year in the United States

66 ilization of more CD34(+) cells (2.7-fold/kg/apheresis), erythroid burst-forming units (1.8-fold/kg/a

67 umab 420 mg subcutaneously monthly, or if on apheresis every 2 weeks.

68 ckground lipid-lowering treatment and not on apheresis, evolocumab 420 mg administered every 4 weeks

69 lds were substantially higher with the first apheresis following rhTPO and G-CSF versus G-CSF alone:

70 efficacy and low incidence of side-effects, apheresis for severe drug-refractory hypercholesterolemi

71 Starting on day 5, patients began daily apheresis for up to 4 days or until > or = 5 x 10(6) CD3

72 Starting on day 5, patients began daily apheresis for up to 4 days or until more than or equal t

73 PSCT patients who received a tumor-negative apheresis harvest was 64%, compared with 57% for patient

74 Selective Lp(a) apheresis has offered some evidence that Lp(a)-lowering

75 Several days later, after apheresis, he received his first of two cycles of high-d

76 GM-CFC threshold was achieved with a single apheresis in 83% of patients and in 90% with two apheres

77 System (JIMRO, Ltd, Takasaki, Japan) or sham apheresis in a 2:1 ratio for 9 weeks of treatment in a N

78 aluated the efficacy of granulocyte/monocyte apheresis in a randomized, double-blind, sham-controlled

79 bear on the evidential basis for therapeutic apheresis in diseases in which hemolytic anemia is a pro

80 easured frequently before, during, and after apheresis in four HIV-1-infected patients, two of whom w

81 counts and consequently platelet yields from apheresis in healthy platelet donors.

82 setting them up, the efficacy of lipoprotein apheresis in homozygous familial hypercholesterolaemia a

83 ong-term benefits of low-density lipoprotein apheresis in severely hypercholesterolemic patients who

84 Lipoprotein apheresis is being performed with increasing frequency,

85 LDL apheresis is currently the best treatment option (or tre

86 Lipoprotein apheresis is indicated for coronary artery disease (CAD)

87 ope have suggested that granulocyte/monocyte apheresis is safe and effective in treating ulcerative c

88 Apheresis is still the treatment of choice in homozygous

89 RECENT FINDINGS: Apheresis is the most efficacious method to lower Lp(a).

90 to assess the effect of chronic lipoprotein apheresis (LA) on the incidence of cardiovascular events

91 Dextran sulfate apheresis lowered circulating sFlt-1, reduced proteinuri

92 in combination with low-density lipoprotein apheresis may confer significant benefits toward prevent

93 ere 17% and 11% for the granulocyte/monocyte apheresis (n = 112)- and sham-treatment groups, respecti

94 emotherapy regimens, and more than 5 days of apheresis needed to harvest enough stem cells were ident

95 Apheresis of multiple donors allowed isolation of autolo

96 aneous daily for 5 days was followed by 12-L apheresis on the fifth day.

97 IdeS treatment, by therapeutic apheresis or direct administration, may be beneficial in

98 ody titres are deemed amenable to removal by apheresis or immunoabsorption.

99 nts such as cell and tissue transplantation, apheresis or parabiosis.Clarifying the source of protein

100 Single-donor apheresis or pooled whole blood-derived platelets in add

101 Each group also received 1 U platelets (apheresis or prepooled random donor) for every 6 U of mW

102 the profound cholesterol-lowering effects of apheresis, other potentially beneficial phenomena have b

103 from reductions achieved in patients not on apheresis (p=0.38 at week 12 and p=0.09 at week 48).

104 CD34(+) cells (median, 7.1 v 2.0 x 10(6)/kg/apheresis; P =.0001), and a higher fraction achieved 2.5

105 her levels of sCD40L than fresh plasma, with apheresis PCs evidencing the highest concentration of sC

106 y-stimulating factor (G-CSF), with the first apheresis performed when the recovery WBC count was > or

107 Pre- and post-apheresis plasma from 6 patients with familial hyperchol

108 Fractionation of pre- and post-apheresis plasma showed that 81 +/- 11% of LDL-bound PCS

109 emia were randomized to receive prophylactic apheresis platelet concentrates when the platelet count

110 We studied ABH expression in 166 group A apheresis platelet donors by flow cytometry, Western blo

111 filtered red blood cell (RBC) units (but not apheresis platelet products) from CMV-positive donors as

112 A single Trima apheresis platelet unit (n = 12) was aliquoted into five

113 n with whole blood platelets (72 reactions), apheresis platelets (2), packed red cells (15), and plas

114 At 2 locations over 3 allergy seasons, apheresis platelets and whole blood were collected from

115 althy donors to provide a median 3-fold more apheresis platelets compared with untreated donors.

116 onducted transfusing radiolabeled autologous apheresis platelets stored for 48 hours at 4 degrees C w

117 To evaluate the poststorage viability of apheresis platelets stored for up to 18 days in 80% plat

118 alents [GE]/mL) resulting in 32 evaluable LR apheresis platelets, 31 filtered platelets from whole bl

119 ts were generally higher for transfusions of apheresis platelets, ABO-identical platelets, and platel

120 a volume components, fresh frozen plasma and apheresis platelets, from potentially alloimmunized dono

121 ts of fresh frozen plasma and 6,251 units of apheresis platelets, we identified 112 patients who rece

122 ion process by adding UDP-galactose to human apheresis platelets.

123 ience of or an equivalent level of safety as apheresis platelets.

124 platelets transfused or transfusing filtered apheresis platelets.

125 pheral procurement of the stem cells through apheresis possible.

126 (+) cells/kg was procured following a single apheresis procedure in 61% of the rhTPO and G-CSF-mobili

127 criteria for lipoprotein apheresis underwent apheresis procedures followed by a second FDG-PET imagin

128 d group of patients, decreases the number of apheresis procedures required, may accelerate hematopoie

129 h A + G compared with G alone required fewer apheresis procedures to reach the target level at least

130 s than 3 x 10(6)/kg and need for more than 2 apheresis procedures.

131 Subsequently, they underwent four to five apheresis procedures.

132 associated with G-CSF administration and the apheresis process included myalgias/arthralgias (83%), h

133 d that filgrastim mobilization, large volume apheresis, processing, and cryopreservation appears to b

134 However, tumor cells contaminating the apheresis product are a potential source of relapse.

135 One apheresis product from each patient was prepared using t

136 units-erythroid (BFU-E) per kilogram in the apheresis product was similar when all patients were ana

137 presumed fetal microchimerism) is present in apheresis products of female donors.

138 Overall, ex vivo treatment of apheresis products with rituximab, bortezomib, and cocul

139 In conclusion, therapeutic apheresis reduced circulating sFlt-1 and proteinuria in

140 or ACS and up to 14 days following the final apheresis/reinfusion session.

141 HDL selective delipidated or control plasma apheresis/reinfusions.

142 ften (17% vs 4%, P< .001), experiencing more apheresis-related AEs (20% vs 7%, P< .001), more bone pa

143 a) levels has been only modestly successful; apheresis remains the most effective therapeutic modalit

144 Our analysis aids in defining apheresis resource utilization and helps in risk stratif

145 studies on nonamplified mRNA from pooled or apheresis samples, respectively.

146 Lipoprotein apheresis seems to be going through a growth spurt, pres

147 this treatment may (1) reduce the number of apheresis sessions and/or amount of G-CSF required to co

148 locyte/monocyte apheresis with the Adacolumn Apheresis System (JIMRO, Ltd, Takasaki, Japan) or sham a

149 n of arterial inflammation after lipoprotein apheresis (TBR: 2.05 +/- 0.31 vs. 1.91 +/- 0.33; p < 0.0

150 Selective apheresis techniques (cytapheresis, immunoadsorption) of

151 cells in the early 1960s, the development of apheresis technology, the discovery of hematopoietic gro

152 n decisions regarding timing and duration of apheresis to harvest a specific number of these cells.

153 titis C virus (HCV) dynamics, we used plasma apheresis to increase virion clearance temporarily while

154 16 microg/kg/d and underwent 1 to 3 days of apheresis to obtain 5 x 10(6) CD34(+) cells per kilogram

155 The use of LDL-apheresis to treat patients with severe hypercholesterol

156 rate that a single dextran sulfate cellulose apheresis treatment reduces circulating sFlt-1 levels in

157 Finally, we performed multiple apheresis treatments in 3 additional women with very pre

158 s after one (n=6), two (n=4), or three (n=1) apheresis treatments.

159 atients who met the criteria for lipoprotein apheresis underwent apheresis procedures followed by a s

160 lower doses equal to one half of a standard apheresis unit are equally effective.

161 e AABB recommends transfusing up to a single apheresis unit or equivalent.

162 tly, the non-evidence-based preponderance of apheresis units in the United States and the 50: 50 rati

163 be accomplished, for example, by therapeutic apheresis using surface-immobilized EndoS.

164 We compared apheresis utilization and transplant outcomes in ABOi, X

165 ics, such as platelet dose, platelet source (apheresis vs pooled), platelet donor-recipient ABO compa

166 The median cell content of the two apheresis was 11.9 x 10(8) WBC/kg, 3.2 x 10(8) CD3/kg, a

167 recipients who received immunoadsorption or apheresis was 94.1% (95% confidence interval [95%CI], 88

168 Transient maternal BP reduction during apheresis was managed by withholding pre-apheresis antih

169 d, multicenter trial of Prosorba versus sham apheresis was performed in patients with RA who had fail

170 Apheresis was performed on 2 consecutive days.

171 In this study, granulocyte/monocyte apheresis was well tolerated but did not demonstrate eff

172 psia (n=22 per group), no adverse effects of apheresis were observed.

173 reductions in LDL cholesterol in patients on apheresis were significant at week 12 (p=0.0012) and wee

174 least 4 weeks, and not receiving lipoprotein apheresis, were randomly allocated by a computer-generat

175 In addition to improving access to apheresis where appropriate, new therapies are needed to

176 or-treated patients reached target after one apheresis, whereas 56% of the placebo-treated patients r

177 safety and potential efficacy of therapeutic apheresis with a plasma-specific dextran sulfate column

178 s intervention, we used granulocyte/monocyte apheresis with the Adacolumn Apheresis System (JIMRO, Lt

179 Apheresis with the Prosorba column is an efficacious tre

180 progenitor cells were observed early during apheresis, with 9 of 12 patients mobilizing adequate amo

181 d 12 weekly treatments with Prosorba or sham apheresis, with efficacy evaluated 7-8 weeks after treat

182 when leukocyte-reduced platelets obtained by apheresis without filtration were also used.